JSPR Jasper Therapeutics, Inc.
Healthcare$0.91+1.06%ClosedMarket Cap: $14.8M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.09
P/S
0.00
EV/EBITDA
-0.02
DCF Value
$1.45
FCF Yield
-469.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-523.0%
ROA
-263.1%
ROIC
-564.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-11.0M | $-1.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-15.8M | $-9.1M | $— | — |
| FY null | $0.00 | -Infinity% | $-80.5M | $-75.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-19.2M | $-18.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-27.1M | $-26.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-21.8M | $-21.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-25.3M | $-24.3M | $— | — |
| FY null | $0.00 | NaN% | $-76.2M | $-71.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-19.9M | $-18.6M | $— | — |
| Q2 null | $0.00 | NaN% | $-16.0M | $-14.6M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-15.1M | $-13.7M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-17.7M | $-16.6M | $-1.50 | — |